Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response

Rosenbaum, C.; Hoven, Andor F. van den; Braat, Manon N.G.J.A.; Koopman, Miriam; Lam, Marnix G. E. H.; Zonnenberg, Bernard A.; Verkooijen, Helena M.; Bosch, Maurice A.A.J. van den

doi:10.1186/s13550-016-0236-1

Cited by 8 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, serum levels of circulating VEGF and PDGF for different time points were significantly different among patients who responded and did not respond to treatment. Similarly, Rosenbaum et al ( 13 ) found a significant increase in serum VEGF, HGF and Ang-2 levels after TARE in 42 CRCLM patients. Carpizo et al ( 9 ) also reported an increase >50% over the baseline in serum angiogenic factor levels in patients who received TARE for HCC and CRCLMs.…”

Section: Discussionmentioning

confidence: 77%

“…However, most of them have been designed to evaluate the angiogenic response after TACE for HCC ( 16 , 17 , 18 , 19 ). In contrast, data on the angiogenic response after TARE for CRC liver metastases are limited to two studies ( 9 , 13 ). For this reason, in this pilot study, we analyzed the angiogenic response after TARE in CRCLM patients.…”

Section: Discussionmentioning

confidence: 99%

“…To date, only three studies have focused on angiogenic markers after TARE ( 9 , 12 , 13 , 14 ), and one included only hepatocellular cancer (HCC) patients ( 12 ). Considering the limited data on this topic, in our pilot study, we included patients with CRCLM and measured circulating angiogenic factors and baseline levels at different time points after TARE.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Soydal

Araz

Durmaz

et al. 2022

Mirt

View full text Add to dashboard Cite

Objectives: To analyze the change in circulating angiogenic factor levels after transarterial radioembolization (TARE) for colorectal cancer liver metastases (CRCLMs) and its prognostic significance Methods: Blood samples immediately before TARE and on 1 day, 1 week and 6 weeks after were collected for angiogenic factor analysis in 23 patients. Results: Patients with elevated serum basic fibroblast growth factor and platelet-derived growth factor levels in the 1 st week and vascular endothelial growth factor (VEGF) levels in the 6 th week after TARE had significantly shorter median overall survival (OS) times. Conclusion: Some early increases in serum angiogenic factor levels and in serum VEGF in the 6 th week after TARE for CRCLMs are related to short OS and progression-free survival.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Soydal

Araz

Durmaz

et al. 2022

Mirt

View full text Add to dashboard Cite

show abstract

“…We found a difference in median OS with and without the presence of extrahepatic metastases at baseline, respectively 7 versus 10 months (p = 0.0018). Several other studies with a comparable patient population also found that extrahepatic disease was a predictor of survival after radioembolization [24,[45][46][47][48][49]. Other known prognostic factors are tumor load, baseline CEA level, and location (left-versus right-sidedness) of the primary tumor [24,49,50].…”

Section: Discussionmentioning

confidence: 93%

Mode of progression after radioembolization in patients with colorectal cancer liver metastases

et al. 2020

View full text Add to dashboard Cite

Background Radioembolization is an established treatment modality in colorectal cancer patients with liver-dominant disease in a salvage setting. Selection of patients who will benefit most is of vital importance. The aim of this study was to assess response (and mode of progression) at 3 months after radioembolization and the impact of baseline characteristics. Methods Three months after radioembolization with either yttrium-90 resin/glass or holmium-166, anatomic response, according to RECIST 1.1, was evaluated in 90 patients. Correlations between baseline characteristics and efficacy were evaluated. For more detailed analysis of progressive disease as a dismal clinical entity, distinction was made between intra- and extrahepatic progression, and between progression of existing metastases and new metastases. Results Forty-two patients (47%) had extrahepatic disease (up to five ≥ 1 cm lung nodules, and ≤ 2 cm lymph nodes) at baseline. No patients showed complete response, 5 (5.5%) patients had partial response, 16 (17.8%) had stable disease, and 69 (76.7%) had progressive disease. Most progressive patients (67/69; 97%) had new metastases (intra-hepatic N = 11, extrahepatic N = 32; or both N = 24). Significantly fewer patients had progressive disease in the group of patients presenting without extrahepatic metastases at baseline (63% versus 93%; p = 0.0016). Median overall survival in patients with extrahepatic disease was 6.5 months, versus 10 months in patients without extrahepatic disease at baseline (hazard ratio 1.79, 95%CI 1.24–2.57). Conclusions Response at 3-month follow-up and survival were heavily influenced by new metastases. Patients with extrahepatic disease at baseline had a worse outcome compared to patients without.

show abstract

“…However, few studies on the existence of the angiogenesis response after TARE have been published. 13,14,24 Only two studies investigate the angiogenesis response after TARE in patients with HCC. Carpizo et al 13 applied TARE with Yttrium-90-loaded on resin microspheres to 22 patients with primary and secondary liver tumors (7 HCC and 15 colorectal carcinoma metastases).…”

Section: Discussionmentioning

confidence: 99%

Short-term changes of angiogenesis factors after transarterial radioembolization in hepatocellular carcinoma patients

Balli¹,

Aikimbaev²,

Güney³

et al. 2023

dir

View full text Add to dashboard Cite

To analyze changes in angiogenesis factors after transarterial radioembolization (TARE) with Yttrium-90-loaded resin microspheres in hepatocellular carcinoma (HCC) patients. METHODSInterleukin-6, interleukin-8, hepatocyte growth factor, platelet-derived growth factor, fibroblast growth factor, vascular endothelial growth factor-A (VEGF-A), and angiopoietin-2 levels in 26 patients were measured before TARE and on day 1, 7, 14, and 30 after TARE and evaluated regarding radiological response. RESULTSIn the sixth month of follow-up, 11 (42.30%) patients had a complete or partial response to treatment, while progressive disease was found in 15 (57.69%) patients. The percentage changes in VEGF-A in the non-responders on day 30 (P = 0.034) after TARE were significantly more obvious. Peak formation rates of VEGF-A were higher in non-responders (P = 0.036). CONCLUSIONShort-term changes in angiogenesis factors in HCC patients after TARE with Yttrium-90-loaded resin microspheres fluctuate with different amplitudes at different times. The upregulation of growth factors has a prognostic capacity. Changes in VEGF-A after TARE may be helpful for the early recognition of non-responders.

show abstract

Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response

Cited by 8 publications

References 32 publications

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Elevated Angiogenic Factor Levels After Transarterial Radioembolization for Colorectal Cancer Liver Metastases May Predict a Poor Prognosis

Mode of progression after radioembolization in patients with colorectal cancer liver metastases

Short-term changes of angiogenesis factors after transarterial radioembolization in hepatocellular carcinoma patients

Contact Info

Product

Resources

About